Insulin dosage advisor for optimal glucose control
| Reference number | |
| Coordinator | Diassist Technology AB |
| Funding from Vinnova | SEK 299 820 |
| Project duration | March 2017 - December 2018 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovativa startups fas 1 Våren 2017 |
Important results from the project
The goal with the project was to evaluate technology developed by Diassist and investigate potential business models. The two parts of the project consisted of: Validation of the prototype through a clinical trial and simulations Further development of business models to gain better insight of business opportunities The goals have been met with satisfactory results.
Expected long term effects
The clinical trial showed that the prototype can estimate if the insulin dosage should be increased or decreased. The expected effect was that the prototype also should be able to estimate insulin dosage for direct use, but this could not be shown. The development of business models gave new insights, as expected and desired.
Approach and implementation
The plan was to evaluate the product and the business model in parallel. The evaluation of the product was delayed, as recruitment of patients took longer time than expected. It has been positive to develop the two parts of the project in parallel at this stage of the product development, but it was complicated to evaluate business opportunities before the performance had been validated.